Current state of renal transplant immunosuppression: Present and future

Table 6 Food and drug administration indications of immunosuppressive agents

Generic	Brand	FDA indication	Company
Basiliximab	Simulect	Prevention of acute rejection in kidney transplantatation	Novartis
Rabbit anti-thymocyte globulin	Thymoglobulin	Treatment of corticosteroid resistant rejection in kidney transplantation	Genzyme
Alemtuzumab	Campath	Treatment of B-cell chronic lymphocytic leukemia	Berlex Laboratories
Efaluzimab	No longer FDA approved Raptiva	Management of moderate to severe chronic plaque psoriasis in adults	Genentech-Merck
Alefacept	Amevive	Treatment of moderate-to-severe chronic plaque psoriasis in adults who are candidates for systemic therapy or phototherapy	Astellas
Tacrolimus prolonged release	Advagraf (in Canada)	Not FDA approved	Astellas
Cyclosporine	Neoral	Prevention of acute rejection in renal transplant recipients	Novartis
Tacrolimus	Prograf	Prevention of acute rejection in renal transplant recipients	Astellas
Voclosporin		Not FDA approved	Isotechnika Pharma
Everolimus	Afinitor, Zortress	Treatment of advanced renal cell cancer (Afinitor®); treatment of subependymal giant cell astrocytom associated with tuberous sclerosis (Afinitor®); treatment of advanced, metastatic or unresectable pancreatic neuroendocrine tumors (Afinitor®); prophylaxis of organ rejection in patients at low-moderate immunologic risk receiving renal transplants (Zortress)	Novartis
Azathioprine	Imuran	Adjunctive therapy in prevention of rejection of kidney transplants; management of active rheumatoid arthritis	Glaxo-Smith-Kline
MMF	Cellcept	Prophylaxis of organ rejection concomitantly with cyclosporine and corticosteroids in patients receiving allogeneic renal cardiac, or hepatic transplants	Genentech
Mycophenolate sodium	Myfortic	Prophylaxis of organ rejection concomitantly with cyclosporine and corticosteroids in patients receiving allogeneic renal transplantation	Novartis
Mizoribine		Not FDA approved	Asahi Kasei Pharma
Sotrastaurin, AEB-071		Not FDA approved	Novartis
Belatacept, BMS224818	Nulojix	Prevention of acute rejection in renal transplant recipients	Bristol-Myers-Squibb
Tolfacitinib, formerly tasocitinib, CP-690550		Not FDA approved	Pfizer
Rituximab	Rituxan	Treatment of CD20-positive non-Hodgkin’s lymphomas; Treatment of moderately- to severely-active rheumatoid arthritis in adult patients with inadequate response to one or more TNF antagonists; Treatment of Wegener’s granulomatosis; Treatment of microscopic polyangiitis	Genentech
Bortezomib	Velcade	Treatment of multiple myeloma; treatment of relapsed or refractory mantle cell lymphoma	Millenium Pharmaceuticals
Eculizumab	Soliris	Treatment of paroxysmal nocturnal hemoglobinuria to reduce hemolysis	Alexion Pharmaceuticals

FDA: Food and drug administration.